• Caught in the debt trap?

    Help us help you by taking our second annual Debt survey and you could win R3 000.

  • Rich man, poor man

    Culture change from below is the only way to overcome poverty, says Leopold Scholtz.

  • Tech bubble talk

    After the tech euphoria of 2013, the fast-moving sector has hit a speed bump.

Data provided by McGregor BFA
All data is delayed
See More

Worth the wait…

Jul 21 2011 00:00 Andile Makholwa

Company Data


Last traded 2.09
Change 0.04
% Change 0.02
Cumulative volume 10108
Market cap 1.17bn

Last Updated: 24/04/2014 at 12:53. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Three must haves

Better than Hotel California

Taking on a T-Rex

Upping the ante

Eyeing further growth

A galaxy of deals

Litha Healthcare – the former AltX-listed counter that merged with Myriad Medical last year and subsequently moved to the JSE’s main board – spends a significant chunk of its 138-page annual report explaining itself and strategic plans for its three divisions for the next couple of years. Understandably, as an AltX player, few investors paid attention to it. Now that it plays in the big league it has to be understood better.

On the face of it, Litha Healthcare Group [JSE:LHG] doesn’t offer much to investors. It’s largely dependent on its biotech business, which supplies paediatric vaccines to South Africa’s Department of Health through a private public partnership (PPP) in The Biovac Institute and, to a limited extent, the private sector. It’s said it’s not about to declare a dividend (maybe in three years’ time), which makes it less attractive to short-term investors.

Nevertheless, we think investors should consider the counter. It’s not yet in the league of Aspen Pharmacare or Adcock Ingram and it certainly can’t be compared to Cipla Medpro. Aside from the obvious fact that pharmaceutical and private hospital groups are defensive stocks, Litha has the making of a potentially successful small cap.

While its PPP with Government gives it a guaranteed income, it’s developing capacity to start manufacturing its own vaccines in 2013 to export it to the rest of southern Africa, venturing into a largely untapped market. Having your own manufacturing division takes it out of just being a distributor and will boost its margins. Equally, there’s potential in its pharma business, especially the focus on generic medicines, while its higher margin medical devices division is poised to increase its sales to the public sector.

As a company emerging from a merger its 2010 financial figures aren’t comparable. However, you can bet on its long-term potential.

Will Afrox remain the same?

2011-08-04 00:00


Company Snapshot

We're Talking About: Small Business

Standard Bank is looking for 12 entrepreneurs to participate in a 10-part TV series. They could win a R1m investment into their dream.

SAPS waited too long to complain about ad - DA

The DA has told a public hearing that the SA Police Service was "hopelessly out of time" to lodge a complaint against its election advert.


Latest elections multimedia

13 days to elections - news you need to know
11 Julius Malema quotes you'll never forget
DA won't get 30% - Zille
The EFF's ad was banned, see why

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...